🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesPrediabetic and scared - will this actually prevent diabetes? Page 2

Prediabetic and scared - will this actually prevent diabetes?

nick_newbie Sat, May 16, 2026 at 8:21 PM 7 replies 449 viewsPage 2 of 2
FDA_TrackerJim
Senior Member
1,567
7,890
Feb 2024
Rockville, MD
May 17, 2026 at 4:23 PM#6
Dr.MetabolicMD said:
PCOS success story with glycaemic control: as someone with polycystic ovary syndrome, this medication has been transformative beyond weight loss.

My labs after 12 months on glycaemic control: A1C 6.1%, fasting glucose 86 mg/dL, fasting insulin 9 uIU/mL. My endo says these are "textbook perfect."

For context, my baseline A1C was 6.7% and fasting glucose was 121 mg/dL. The improvement has been dramatic and consistent.

1 21Dr.Martinez
Reply Quote Save Share Report
Dr.PeteFamMed
Senior Member
2,012
9,234
Jan 2024
Minneapolis, MN
May 18, 2026 at 12:20 AM#7
nick_newbie said:
A1C went from 7.4 to 5.6 over nine months and my prescriber was more interested in the fasting insulin, which I did not expect.

Complete metabolic panel trending on glycaemic control — sharing because comprehensive data helps everyone:

TestBaselineMonth 3Month 6Month 12
Glucose (fasting)1181049082
Insulin (fasting)2412105
HOMA-IR4.53.41.81.2
Uric Acid8.16.85.74.9

The insulin resistance improvement (HOMA-IR) is what my endo focuses on most. Going from 4.5 to near 1.0 is a metabolic transformation.

Last edited: May 18, 2026 at 1:20 AM
50 20tommy_boulder, hyun_seoul, jim_asheville and 47 others
Reply Quote Save Share Report
MASHdoc_SA
Member
456
2,345
Aug 2024
San Antonio, TX
May 18, 2026 at 8:17 AM#8
FDA_TrackerJim said:
My labs after 12 months on glycaemic control: A1C 6.1%, fasting glucose 86 mg/dL, fasting insulin 9 uIU/mL.

Insulin sensitivity test (HOMA-IR) on glycaemic control — arguably the most important metabolic marker most people aren't tracking:

HOMA-IR = (fasting insulin × fasting glucose) ÷ 405

My numbers: Baseline HOMA-IR = 4.7 (insulin resistant) → Current = 1.3 (insulin sensitive)

Anything above 2.0 indicates insulin resistance. The goal is below 1.5. GLP-1 agonists address the root metabolic dysfunction, not just the symptoms. This is why they work so much better than calorie restriction alone.

49 19JennaRN, LabKate, kate.chem and 46 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
jennifer_SEA
Member
234
890
Nov 2024
Seattle, WA
May 18, 2026 at 4:14 PM#9

A narrower follow-up, since the general answer is now clear:

What would you measure differently if you were starting again?

Last edited: May 18, 2026 at 10:14 PM
48 18jim_asheville, matt_MKE, Dr.ReproEndo and 45 others
Reply Quote Save Share Report
nick_newbie
New Member
18
56
Jun 2026
Virginia
Online
May 20, 2026 at 6:23 AM#10
MASHdoc_SA said:
Insulin sensitivity test (HOMA-IR) on glycaemic control — arguably the most important metabolic marker most people aren't tracking: HOMA-IR = (fasting…

Fasting insulin is the lab my functional medicine doctor cares about most for glycaemic control: it's a much earlier marker of metabolic dysfunction than glucose or A1C.

My fasting insulin: 27 → 15 → 5 uIU/mL over 9 months. Target is <7. By the time your fasting glucose is elevated, your insulin has been elevated for YEARS trying to compensate.

Ask your doctor to include fasting insulin in your bloodwork panel. It's cheap (~$20) and incredibly informative.

36 11wanda_boise, NurseAsh_DET, BenResearch_OR and 33 others
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register